- Home
- LBTYA vs IMVT Comparison
LBTYA vs IMVT Comparison
Compare LBTYA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYA
- IMVT
- Stock Information
- Founded
- LBTYA 2004
- IMVT N/A
- Country
- LBTYA Bermuda
- IMVT United States
- Employees
- LBTYA N/A
- IMVT N/A
- Industry
- LBTYA Cable & Other Pay Television Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LBTYA Telecommunications
- IMVT Health Care
- Exchange
- LBTYA Nasdaq
- IMVT Nasdaq
- Market Cap
- LBTYA 4.0B
- IMVT 3.4B
- IPO Year
- LBTYA N/A
- IMVT N/A
- Fundamental
- Price
- LBTYA $11.51
- IMVT $17.09
- Analyst Decision
- LBTYA Strong Buy
- IMVT Strong Buy
- Analyst Count
- LBTYA 3
- IMVT 11
- Target Price
- LBTYA $19.67
- IMVT $44.13
- AVG Volume (30 Days)
- LBTYA 1.9M
- IMVT 1.8M
- Earning Date
- LBTYA 05-02-2025
- IMVT 02-06-2025
- Dividend Yield
- LBTYA N/A
- IMVT N/A
- EPS Growth
- LBTYA N/A
- IMVT N/A
- EPS
- LBTYA 4.23
- IMVT N/A
- Revenue
- LBTYA $4,341,900,000.00
- IMVT N/A
- Revenue This Year
- LBTYA $2.03
- IMVT $108.88
- Revenue Next Year
- LBTYA N/A
- IMVT N/A
- P/E Ratio
- LBTYA $2.73
- IMVT N/A
- Revenue Growth
- LBTYA 5.49
- IMVT N/A
- 52 Week Low
- LBTYA $10.55
- IMVT $16.72
- 52 Week High
- LBTYA $21.56
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- LBTYA 47.37
- IMVT 35.78
- Support Level
- LBTYA $11.47
- IMVT $17.49
- Resistance Level
- LBTYA $11.86
- IMVT $18.96
- Average True Range (ATR)
- LBTYA 0.29
- IMVT 1.24
- MACD
- LBTYA -0.01
- IMVT -0.09
- Stochastic Oscillator
- LBTYA 30.00
- IMVT 9.95
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in several telecom companies in the UK, the Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies, and has pursued a strategy since 2016 to merge or partner with mobile-network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).